Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Sep82020
News

Demand for FDA Action Amid Shuffle

Sarah Owermohle, Zachary Brennan and David Lim | Politico

“The president’s executive order for CMS to finalize a rule eliminating rebates that drugmakers pay to pharmacy benefit managers had one big caveat — the rule cannot raise seniors’ premiums, out-of-pockets costs or federal spending.

That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”

Read Here

September 8, 2020Category: News
Tags: drug pricingMedicareprescription drugsrebates

Post navigation

PreviousPrevious post:Efficient and Targeted Tax Policy During the Coronavirus PandemicNextNext post:New MGA Report on the Negative Economic Impact of Restricting Drug Rebates in Medicare Part D
  • Analysis(29)
  • Books(2)
  • Events(13)
  • Interviews(37)
  • News(46)
  • Op-Eds(63)
  • Press Releases(2)
  • Testimony(19)
  • Alex Brill Talks Trade Disruption Due to Suez Canal Blockage on i24 News
    March 31, 2021
  • Alex Brill Featured in Foundation for Economic Education Article
    March 26, 2021
  • U.S. Spending and Tax Policy After the COVID Recessions: Political Economy Podcast
    March 24, 2021
  • Alex Brill Testifies Before U.S. Senate on Lowering Prescription Drug Prices
    March 23, 2021

Website Design and Developed by DreamBig Creative